STA
IRWD icon

Summit Trail Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Summit Trail Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-653
Closed -$8K – 1050
2017
Q4 		$8K Buy
+653
New +$8.53K ﹤0.01% 1280

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Summit Trail Advisors's IRWD Position: Q1 2018 in Review

Summit Trail Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2018, closing a stake of 653 shares — an estimated $8K sold.

Summit Trail Advisors first reported a position in IRWD in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 149 funds tracked by Wall St. Rank hold IRWD as of Q1 2018.

  • Summit Trail Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 653 Ironwood Pharmaceuticals shares in Q1 2018, an estimated $8K.
  • Summit Trail Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Ironwood Pharmaceuticals position peaked at $8K in Q4 2017.
  • 149 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.